 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| MGC026 / MacroGenics
Enrollment open: A Study of MGC026 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 15, 2024
P1, N=230, Recruiting, Sponsor: MacroGenics
Not yet recruiting --> Recruiting
- MGC026 / MacroGenics
Preclinical development of MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3 for solid cancer (Section 23) - Mar 5, 2024 - Abstract #AACR2024AACR_3904;
MGC026 was tolerated in cynomolgus monkeys, a relevant toxicology model, at exposure levels exceeding those required for antitumor activity. These data support clinical development of MGC026 for the treatment of B7-H3-expressing solid cancers.
- ||| MGC026 / MacroGenics
New P1 trial: A Study of MGC026 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Feb 5, 2024
P1, N=230, Not yet recruiting, Sponsor: MacroGenics